Randomized trial · people

Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg arm

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In this 48-week trial, weight loss with retatrutide grew with dose, gut side effects were the most common, and a lower starting dose partly eased them.

Kind
Randomized trial
Studied in
People
Number studied
338
Published
2023
Journal
N Engl J Med

What they tested

The team wanted to learn how different weekly doses of retatrutide relate to weight loss, side effects and safety in adults with obesity.

How the study was done

A phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with a BMI (body-mass index, weight relative to height) of 30 or higher, or 27 to under 30 with at least one weight-related condition. Participants got a weekly shot under the skin of retatrutide at 1 mg, 4 mg, 8 mg or 12 mg (some arms started at a lower dose) or placebo, a dummy shot, for 48 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 24 weeks, the main goal, average body weight changed by -7.2% in the 1 mg arm, -12.9% in the combined 4 mg arms, -17.3% in the combined 8 mg arms and -17.5% in the 12 mg arm, compared with -1.6% on placebo. At 48 weeks, the changes were -8.7%, -17.1%, -22.8% and -24.2%, compared with -2.1% on placebo. By 48 weeks, a loss of 15% or more was seen in 60% of the 4 mg group, 75% of the 8 mg group and 83% of the 12 mg group, compared with 2% on placebo. Stomach and gut side effects were the most common, rose with dose, were mostly mild to moderate and were partly eased by starting at 2 mg instead of 4 mg. Heart rate also went up with dose, peaked at 24 weeks and then came down.

What it doesn’t show

This was a mid-stage trial of 338 people lasting 48 weeks, so it doesn't show longer-term results or rarer side effects. It was funded by Eli Lilly.

The paper

Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo